Unlocking the Potential of NOD2
Laurentide Therapeutics is developing a novel class of NOD2 agonists designed to harness the body's innate immune system while avoiding the inflammatory limitations that have constrained previous approaches.
A Powerful Target. A New Opportunity.
NOD2 is one of the body's key regulators of innate immunity, with therapeutic potential across infectious, inflammatory and neurodegenerative diseases. Although decades of research have demonstrated its promise, progress has been limited because existing NOD2 agonists can trigger unwanted inflammatory responses.
Laurentide is developing a differentiated approach designed to unlock the therapeutic potential of this important biological pathway.
NOVEL SCIENCE
A proprietary LDPP platform designed to selectively modulate NOD2 biology.
HOST-DIRECTED
Activating the body's own immune response rather than directly targeting pathogens.
BROAD POTENTIAL
A platform with potential applications across multiple disease areas.
Advancing a Platform for Multiple Diseases
Laurentide is evaluating the potential of its platform across multiple therapeutic areas while advancing its lead viral disease program.
Inflammatory
Bowel Disease
Viral Disease
Neuroinflammatory
Disease
